The Challenge
Aggressive TNBC with numerous tumor masses and limited standard options.
Our Impact
We connected her to a clinical trial with a novel combination therapy based on early promising data. We also suggested an adjuvant immunochemotherapy plan informed by clinical trial data to further reduce recurrence risk.
The Outcome
Complete pathologic response—no cancer remained after surgery. Remains cancer-free with adjuvant therapy.
